SCHEMBL15042889

SCHEMBL15042889

CC(C)c1cc2c(ncc3c(C(C)C)cccc32)[nH]1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 1/20 0.35
PDK4 Q16654 1/20 0.35
IKBKB O14920 2/20 0.34
CHUK O15111 2/20 0.34
LMNA P02545 2/20 0.34
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
ADRA1A P35348 2/20 0.33
ADRA1D P25100 1/20 0.33
ADRA1B P35368 1/20 0.33
TSHR P16473 2/20 0.32
FAAH O00519 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GABRA1 P14867 1/20 0.32
HPGD P15428 1/20 0.32
GABRB1 P18505 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19485909 0.81 IKBKB (0.37) PDK2PDK4IKBKBCHUKLMNA
SCHEMBL15042846 0.78 KDM5A (0.33) LMNAADRA2AADRA2BADRA2CADRA1A
SCHEMBL24139779 0.76 IKBKB (0.46) IKBKBCHUKTSHRDHFRSLC2A1
SCHEMBL15042893 0.73 DHFR (0.41) LMNATSHRFAAHCA1CA2
SCHEMBL24371171 0.72 DHFR (0.42) LMNATSHRFAAHCA1CA2
SCHEMBL15042876 0.72 GABRA1 (0.40) LMNAGABRA1GABRB1GABRG2GABRB3
SCHEMBL15042888 0.70 AURKA (0.37) IKBKBCHUKADRA2AADRA2BADRA2C
SCHEMBL15042847 0.68 LMNA (0.41) PDK2PDK4LMNAADRA2AADRA2B
SCHEMBL19486057 0.66 PARP1 (0.34) LMNATSHRCYP1A2CYP3A4GABRA1
SCHEMBL12294488 0.66 ADORA3 (0.40) PDK2LMNAADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796705-B2 Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases MERCK SHARP & DOHME CORP. (US) 2017-10-24 US disclosed
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES MERCK SHARP & DOHME CORP. (US) 2017-01-12 US disclosed
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS SCHERING CORPORATION 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130156731-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS HAVCR2, ELOC, ZC3HAV1 PDK2 3587/4885PDK4 2594/4885IKBKB 1553/4885
US-20170008879-A1 FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES ZC3HAV1, HAVCR2, ZC3HAV1L PDK2 3104/4885PDK4 2198/4885IKBKB 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.